Enjuanes, Anna <br/><br/>
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.  [electronic resource] 

 -  Endocrine  Feb 2010 
 - 180-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1559-0100 
<br/><br/><label>Standard No.: </label>10.1007/s12020-009-9285-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Alendronate--adverse effects<br/>Alkaline Phosphatase--metabolism<br/>Bone Density Conservation Agents--adverse effects<br/>Cell Differentiation--drug effects<br/>Cell Survival--drug effects<br/>Cells, Cultured<br/>Gene Expression Regulation--drug effects<br/>Humans<br/>Middle Aged<br/>Osmolar Concentration<br/>Osteoblasts--drug effects<br/>Osteocalcin--genetics<br/>Osteoporosis--drug therapy<br/>Osteoprotegerin--genetics<br/>RANK Ligand--genetics<br/>RNA, Messenger--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Time Factors<br/>Vitamin D--metabolism